Retour

Palisade Bio Appoints Margery Fischbein to its Board of Directors

News Press releases

Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally

GlobeNewswire Inc. • 07/05/2024 à 14:30:00
Palisade Bio, Inc. Common Stock
Address: 7750 EL CAMINO REAL, SUITE 5200
Postal Code: 92009
City: CARLSBAD
State: CA
Phone Number: (858) 704-4900
Website: https://www.palisadebio.com
Status: Active
Company Info

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

List Date2021-04-28
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001357459
Composite figiBBG000QG4DJ2
Share Class figiBBG001SS4KZ8
Market Cap5,962,894 USD
SIC Code2836
SIC DescriptionBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Total Employees9
Share Class Shares Outstanding940000
Weighted Shares Outstanding937562
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
6.435
6.375
6.415
6.29
6.195
Variance
0.94%
-0.62%
2.8%
1.53%
-9.12%
Open
6.375
6.415
6.24
6.195
6.817
Highest
6.944
6.55
6.575
6.4
6.817
Lowest
6.496
6.55
6.575
6.4
6.615
History
PeriodVarhighestlowest
1 week
-5.6%
6.817
6.4
1 month
37.35%
5.225
5.225
3 month
1362.5%
0.443
0.376
6 month
963.64%
0.6275
0.376
1 year
309.87%
1.57
0.376
3 year
-96.51%
192
0.376
5 year
-98.57%
545.5
0.376
10 year
-98.57%
545.5
0.376
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Assets 15,262,000 18,290,000 17,067,000 UNPUB
Current Assets 14,309,000 17,411,000 16,266,000 UNPUB
Current Liabilities 1,315,000 2,335,000 2,649,000 UNPUB
Equity 13,747,000 15,800,000 14,082,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 13,747,000 15,800,000 14,082,000 UNPUB
Liabilities 1,515,000 2,490,000 2,985,000 UNPUB
Liabilities And Equity 15,262,000 18,290,000 17,067,000 UNPUB
Noncurrent Assets 953,000 879,000 801,000 UNPUB
Noncurrent Liabilities 200,000 155,000 336,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 4,020,000 -1,091,000 UNPUB
Net Cash Flow, Continuing 0 4,020,000 -1,091,000 UNPUB
Net Cash Flow From Financing Activities 4,440,000 5,309,000 1,571,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 4,440,000 5,309,000 1,571,000 UNPUB
Net Cash Flow From Investing Activities -914,000 910,000 0 UNPUB
Net Cash Flow From Investing Activities, Continuing -914,000 910,000 0 UNPUB
Net Cash Flow From Operating Activities -3,526,000 -2,199,000 -2,662,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -3,526,000 -2,199,000 -2,662,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Comprehensive Income/Loss -2,340,000 -3,393,000 -3,596,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -2,340,000 -3,393,000 -3,596,000 UNPUB
Other Comprehensive Income/Loss 0 0 0 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-09 UNPUB
Basic Earnings Per Share -1 -1 0 UNPUB
Benefits Costs and Expenses 0 0 0 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 2,779,000 3,609,000 3,778,000 UNPUB
Diluted Earnings Per Share -1 -1 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -2,340,000 -3,393,000 -3,596,000 UNPUB
Income/Loss From Continuing Operations Before Tax 250,000 -3,393,000 -3,596,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating 0 3,000 8,000 UNPUB
Net Income/Loss -2,340,000 -3,393,000 -3,596,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -2,340,000 -3,393,000 -3,596,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -2,340,000 -3,393,000 -3,612,000 UNPUB
Operating Expenses 2,779,000 3,609,000 3,778,000 UNPUB
Operating Income/Loss -2,529,000 -3,609,000 -3,778,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 16,000 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 16,000 UNPUB
Revenues 250,000 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-15 2022-11-14 2023-03-22
Assets 8,350,000 7,806,000 16,266,000 15,763,000
Current Assets 8,258,000 7,415,000 15,158,000 14,733,000
Current Liabilities 1,864,000 2,860,000 3,513,000 3,012,000
Equity 4,792,000 4,211,000 12,430,000 12,479,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 4,792,000 4,211,000 12,430,000 12,479,000
Liabilities 3,558,000 3,595,000 3,836,000 3,284,000
Liabilities And Equity 8,350,000 7,806,000 16,266,000 15,763,000
Noncurrent Assets 92,000 391,000 1,108,000 1,030,000
Noncurrent Liabilities 0 0 323,000 272,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-15 2022-11-14 2023-03-22
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 1,888,000
Net Cash Flow, Continuing 0 0 0 1,888,000
Net Cash Flow From Financing Activities -87,000 1,586,000 12,045,000 15,258,000
Net Cash Flow From Financing Activities, Continuing -87,000 1,586,000 12,045,000 15,258,000
Net Cash Flow From Investing Activities 3,851,000 1,664,000 -9,005,000 -10,000
Net Cash Flow From Investing Activities, Continuing 3,851,000 1,664,000 -9,005,000 -10,000
Net Cash Flow From Operating Activities -3,764,000 -3,250,000 -3,040,000 -13,360,000
Net Cash Flow From Operating Activities, Continuing -3,764,000 -3,250,000 -3,040,000 -13,360,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-15 2022-11-14 2023-03-22
Comprehensive Income/Loss -4,205,000 -2,344,000 -3,991,000 -14,260,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -4,205,000 -2,344,000 -3,991,000 -14,260,000
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-13 2022-08-15 2022-11-14 2023-03-22
Basic Earnings Per Share 0 0 0 -17
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 0 0 -17
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -4,205,000 -2,344,000 -3,991,000 -14,260,000
Income/Loss From Continuing Operations Before Tax -4,205,000 -2,344,000 -3,991,000 -14,260,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating 1,000 5,000 4,000 13,000
Net Income/Loss -4,205,000 -2,344,000 -3,991,000 -14,260,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -4,205,000 -2,344,000 -3,991,000 -14,260,000
Net Income/Loss Available To Common Stockholders, Basic -4,205,000 -2,344,000 -3,991,000 -14,548,000
Operating Expenses 3,888,000 3,572,000 4,413,000 15,721,000
Operating Income/Loss -3,888,000 -3,572,000 -4,413,000 -15,721,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 288,000
Preferred Stock Dividends And Other Adjustments 0 0 0 288,000
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-23 2021-11-12 2022-03-17
Assets UNPUB 14,949,000 16,274,000 12,512,000
Current Assets UNPUB 14,725,000 16,092,000 12,374,000
Current Liabilities UNPUB 3,850,000 2,920,000 2,496,000
Equity UNPUB -9,444,000 3,920,000 7,365,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB -9,444,000 3,920,000 7,365,000
Liabilities UNPUB 24,393,000 12,354,000 5,147,000
Liabilities And Equity UNPUB 14,949,000 16,274,000 12,512,000
Noncurrent Assets UNPUB 224,000 182,000 138,000
Noncurrent Liabilities UNPUB 0 9,434,000 2,651,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-23 2021-11-12 2022-03-17
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB 15,881,235 1,451,000 9,782,000
Net Cash Flow, Continuing UNPUB 15,881,235 1,451,000 9,782,000
Net Cash Flow From Financing Activities UNPUB UNPUB 4,545,000 24,609,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 4,545,000 24,609,000
Net Cash Flow From Investing Activities UNPUB UNPUB -348,000 -54,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -348,000 -54,000
Net Cash Flow From Operating Activities UNPUB -5,030,765 -2,746,000 -14,773,000
Net Cash Flow From Operating Activities, Continuing UNPUB -5,030,765 -2,746,000 -14,773,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-23 2021-11-12 2022-03-17
Comprehensive Income/Loss UNPUB -31,746,000 8,087,000 -26,616,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -31,746,000 8,087,000 -26,616,000
Other Comprehensive Income/Loss UNPUB 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2021-08-23 2021-11-12 2022-03-17
Basic Earnings Per Share UNPUB -4 0 -3
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB -4 0 -3
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -31,746,000 8,087,000 -26,616,000
Income/Loss From Continuing Operations Before Tax UNPUB -31,746,000 8,087,000 -26,616,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB 655,000 26,000 2,398,000
Net Income/Loss UNPUB -31,746,000 8,087,000 -26,616,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -31,746,000 8,087,000 -26,616,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -31,746,000 5,118,000 -26,616,000
Operating Expenses UNPUB 32,858,000 3,016,000 41,854,000
Operating Income/Loss UNPUB -32,858,000 -3,016,000 -41,854,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 0
Preferred Stock Dividends And Other Adjustments UNPUB 0 2,969,000 0
Revenues UNPUB 0 0 0
Calendar
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
★
15:30
United States
News Stream
News Press releases
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end
GlobeNewswire Inc. • 5d ago
News Press releases
Palisade Bio Appoints Margery Fischbein to its Board of Directors
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally
GlobeNewswire Inc. • 1w ago
News Press releases
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has entered into a definitive agreement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded warrants in lieu thereof) in a private placement at a purchase price per share of $6.5015, priced at-the-market under Nasdaq rules. The Company expects to receive gross proceeds of approximately $4 million, before deducting placement agent fees and other offering expenses payable by the Company.
GlobeNewswire Inc. • 2w ago
News Press releases
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end
GlobeNewswire Inc. • 2w ago
News Press releases
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
– Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics
GlobeNewswire Inc. • 3w ago
News Press releases
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
– Live webcast with members of Palisade Bio management on Tuesday, April 16th at 12:00 PM ET
GlobeNewswire Inc. • 1mo ago
News Press releases
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end
GlobeNewswire Inc. • 1mo ago
News Press releases
Palisade Bio Announces 1-for-15 Reverse Stock Split
Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced a 1-for-15 reverse split of its common stock, par value $0.01 (“Common Stock”), effective at 5:00 PM ET on Friday April 5, 2024. Beginning on Monday, April 8, 2024, the Company’s Common Stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) on a split adjusted basis under the trading symbol “PALI,” but will trade under the following new CUSIP number starting April 8, 2024: 696389402.
GlobeNewswire Inc. • 1mo ago
News Press releases
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024.
GlobeNewswire Inc. • 3mo ago
News Press releases
Palisade Bio Provides Corporate Update and Reiterates Guidance
– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision
GlobeNewswire Inc. • 3mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT